Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   pharming juli 2016

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,913   -0,033   (-3,49%) Dagrange 0,909 - 0,955 12.416.075   Gem. (3M) 6,7M

pharming juli 2016

Volgen
2.488 Posts
Pagina: «« 1 ... 101 102 103 104 105 ... 125 »» | Laatste | Omlaag ↓
  1. [verwijderd] 27 juli 2016 22:42
    quote:

    beurs aapje2 schreef op 27 juli 2016 21:44:

    www.tostrams.nl/artikel-detail.aspx?I... morgen weer eens kijken boven de 0,24 en als het weer eens een dag word van 30 miljoen stuks kan het een echt feestje worden
    Grappig, website is uit te lezen aan de hand van een blind sql injection. Iemand die de DB even leeg wilt trekken en op pastebin wilt zetten?
  8. [verwijderd] 28 juli 2016 07:02
    Pharming Reports on Financial Results for the First Six Months of 2016
    Print Friendly

    Leiden, The Netherlands, 28 July 2016: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) announces its (unaudited) financial report for the six months ended 30 June 2016.

    The Company will hold a conference call at 10:00 CET today, dial-in details can be found on page 7.

    Highlights

    Sales of RUCONEST® up 63% overall in second quarter relative to first quarter, so that sales in the first half of 2016 sales were slightly ahead of the first half of 2015
    Sales in the USA up by approximately 33% in the second quarter compared with the first quarter
    Gross Profit increased by 14% for the half year compared with the first half of 2015
    Strongly Positive Results from Phase II study of RUCONEST® for prophylaxis of HAE
    Pharming agrees to market RUCONEST directly in 21 more EU and Middle East countries in amendment with SOBI

    CEO’s Commentary

    After a relatively modest start to sales of RUCONEST® (recombinant C1 esterase inhibitor, 50 IU/kg) in 2016, sales trends during the second quarter improved again. More consistent sales efforts in the US, recovering from the impact of a significant reorganization of the Valeant sales force in Q4 2015, and a modest expansion in our EU direct commercialization efforts drove these improvements. Pharming is continually looking for ways to improve sales performance in the USA and the rest of the world in cooperation with our partners.

    Income from sales increased 63% from €1.6 million in the first quarter to €2.6 million in the second quarter, with sales in the USA up from €1.5 million in the first quarter to €2.0 million in the second quarter. This represents a good half year, and exceeds the first half of 2015 when the major wholesalers in the USA were ramping up their stocking levels of RUCONEST® to meet increasing demand. Gross profits from sales continue to increase as well; from €1.6 million in the first quarter to €1.7 million in the second quarter of 2016 as result of the changing mix between US sales and sales in the EU by Swedish Orphan Biovitrum (“SOBI”) and by Pharming. We continued to keep pressure on cash expenditure despite the improvement, resulting in resource management improvement in the first half of 2016 compared with the first half of 2015.

    During March, the European Commission adopted the CHMP recommendation to include the treatment of hereditary angioedema (“HAE”) attacks in adolescents and to remove the requirements for rabbit IgE testing that previously formed part of the EU label for RUCONEST®. The CHMP also noted that the importance of favorable effects of RUCONEST® is further supported by the continued availability of supply of RUCONEST® (produced by recombinant technology) in comparison to supply from blood donor plasma that may vary, and that as it is not a blood derived product RUCONEST® carries no potential risk of exposure to blood-borne pathogens.

    We continue to make good progress in developing our pipeline to produce the next generation of therapies from our platform. Our first program lead for Pompe disease is now entering its next stage of pre-clinical testing and process development with the second program for Fabry Disease following by approximately six months. We will be announcing details of these programs and the timetable of their clinical development later this year.

    After the end of the period we updated our distribution agreement with SOBI. As of 1 October this year, Pharming will commercialize RUCONEST® directly in a further 21 countries. SOBI had not yet begun significant sales efforts in most of these countries. The countries include the major EU markets of the UK, France and Spain, and a number of countries across Europe and the Middle East which do not yet have optimal access to therapies for HAE. In some of these countries we will continue to act in partnership with the HAEi Global Access Program.

    Earlier this month we also announced positive results from a Phase 2 clinical study of RUCONEST® for prophylaxis in patients with HAE. In the study, RUCONEST® showed a clinically relevant and statistically significant reduction in attack frequency for both the twice-weekly (p-value <0.0001) and once-weekly (p-value = 0.0004) treatment regimens as compared with placebo. The secondary endpoint showed a response rate of up to 96% in the twice weekly treated per protocol group of patients, corroborating reports from day-to-day use of RUCONEST. At present, there is only one product formally approved for treatment of prophylaxis of HAE in the USA, and the market is expected to be around $800 million in 2017. This represents a huge potential market for RUCONEST®, which if approved would be the only product approved for both acute attacks and prophylactic therapy. More detail is given below.

    Based on our financial results for the first half of 2016, we expect that both sales and gross profits will continue to improve during the remainder of the year and that investments in R&D will continue to increase gradually, following the sales trends.

    No further financial guidance is provided

    Sijmen de Vries
    Chief Executive Officer
  18. Sjonnie2 28 juli 2016 07:34
    quote:

    Hoopmazzel schreef op 28 juli 2016 07:25:

    Verlies van 3.5 miljoen naar 6.7 miljoen.de kaspositie van 31 naar 21 miljoen.
    De zoveelste aandelen emissie hangt alweer in de lucht !, maar Sijmen hangt de opgewarmde worst tijdens de conference call weer voor de beleggers met de overname van een failliet Frans bedrijf.
    Het is steeds hetzelfde liedje: voor de cijfers de koers oppompen en de dag voor de cijfers staat het weer op het oude lagere niveau.
2.488 Posts
Pagina: «« 1 ... 101 102 103 104 105 ... 125 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. Morgan Stanley groter in Pharming
  2. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  3. RBC verhoogt koersdoel Pharming fors
  4. Afwachtend begin van Super Central Bank-week en we hebben een beursganger
  5. CEO De Vries: Pharming dicht bij overname van nieuwe blockbuster
  6. Pharming brengt bod op Abliva AB uit
  7. Moeizame week voor financials
  8. Weekoverzicht: vastgoed uit de gratie, winst voor automotive en chipaandelen
  9. Fundlogic verkleint belang in Pharming
  10. Fundlogic meldt belang in Pharming